Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 0.38 |
| ▸ | PGK2 | P07205 | 1/20 | 0.38 |
| ▸ | PGD | P52209 | 4/20 | 0.36 |
| ▸ | MPI | P34949 | 1/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.36 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.33 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL429247 | 0.80 | PGD (0.45) | PGK1PGK2PGDMPILPAR1 | |
| SCHEMBL5297305 | 0.80 | PGD (0.45) | PGK1PGK2PGDMPILPAR1 | |
| SCHEMBL16424696 | 0.78 | TDP1 (0.36) | — | |
| SCHEMBL10226926 | 0.72 | TSHR (0.33) | — | |
| SCHEMBL5594382 | 0.72 | ENPP2 (0.50) | PGK1PGK2PGDMPILPAR1 | |
| SCHEMBL11326756 | 0.71 | S1PR1 (0.44) | PGK1PGK2PGDLPAR1LPAR3 | |
| SCHEMBL15571791 | 0.71 | S1PR1 (0.41) | PGK1PGK2PGDLPAR1LPAR3 | |
| SCHEMBL19462882 | 0.70 | PGK1 (0.43) | PGK1PGK2PGDMPILPAR1 | |
| SCHEMBL17338080 | 0.70 | PGK1 (0.43) | PGK1PGK2PGDMPILPAR1 | |
| SCHEMBL680243 | 0.70 | PGK1 (0.43) | PGK1PGK2PGDMPILPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9827332-B2 | Modified polynucleotides for the production of proteins | MODERNATX, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9790531-B2 | Enzymes and polymerases for the synthesis of RNA | MODERNATX, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9782462-B2 | Modified polynucleotides for the production of proteins associated with human disease | MODERNATX, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170130255-A1 | ENZYMES AND POLYMERASES FOR THE SYNTHESIS OF RNA | MODERNATX, INC. (US) | 2017-05-11 | — | — | US | disclosed |
| US-9428535-B2 | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof | MODERNA THERAPEUTICS, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-20160151516-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2016-06-02 | — | — | US | disclosed |
| US-9221891-B2 | In vivo production of proteins | MODERNA THERAPEUTICS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150111248-A1 | IN VIVO PRODUCTION OF PROTEINS | MODERNA THERAPEUTICS, INC. (US) | 2015-04-23 | — | — | US | disclosed |
| US-20150064235-A1 | MODIFIED POLYNUCLEOTIDES | ARES CAPITAL CORPORATION, AS AGENT | 2015-03-05 | — | — | US | disclosed |
| US-20150050354-A1 | MODIFIED POLYNUCLEOTIDES FOR THE TREATMENT OF OTIC DISEASES AND CONDITIONS | MODERNATX, INC. | 2015-02-19 | — | — | US | disclosed |
| US-20140155473-A1 | MODIFIED GLUCOSIDASE, BETA, ACID POLYNUCLEOTIDES FOR TREATING PROTEIN DEFICIENCY | Moderna Threrapeutics, Inc. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20130115272-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150050354-A1 | MODIFIED POLYNUCLEOTIDES FOR THE TREATMENT OF OTIC DISEASES AND CONDITIONS | OTC, POLRMT, POLN | PGK1 2201/4885PGK2 1536/4885PGD 3814/4885 |
| US-20160151516-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS | POLRMT, MSH2, POLN | PGK1 2241/4885PGK2 1769/4885PGD 3854/4885 |
| US-20150064235-A1 | MODIFIED POLYNUCLEOTIDES | POLRMT, POLN, MSH2 | PGK1 2736/4885PGK2 2267/4885PGD 4507/4885 |
| US-20150111248-A1 | IN VIVO PRODUCTION OF PROTEINS | MSH2, POLRMT, POLN | PGK1 3118/4885PGK2 2888/4885PGD 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.